Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer
This study has been completed.
Daniela Matei, MD
Walther Cancer Institute
Information provided by (Responsible Party):
Daniela Matei, MD, Hoosier Cancer Research Network
First received: September 12, 2005
Last updated: February 17, 2016
Last verified: February 2016
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||July 2007|
|Primary Completion Date:||October 2005 (Final data collection date for primary outcome measure)|
Matei D, Emerson RE, Schilder J, Menning N, Baldridge LA, Johnson CS, Breen T, McClean J, Stephens D, Whalen C, Sutton G. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial. Cancer. 2008 Aug 15;113(4):723-32. doi: 10.1002/cncr.23605.